NEW YORK (GenomeWeb News) – Counsyl, a company that provides carrier screening and genetic testing for inherited conditions, has taken the preemptive action of asking a California federal district court to determine that it wouldn't be infringing Myriad Genetics' patent claims on BRCA 1 and BRCA 2 genes if it were to offer testing on those genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.